

1. Hofer SJ, Carmona-Gutierrez D, Mueller MI, Madeo F. The ups and downs of caloric restriction and fasting: from molecular effects to clinical application. *EMBO Molecular Medicine*. 2022 Jan 11;14(1):e14418.
2. Soliman GA. Intermittent fasting and time-restricted eating role in dietary interventions and precision nutrition. *Frontiers in Public Health* [Internet]. 2022 [cited 2023 Aug 1];10. Available from: <https://www.frontiersin.org/articles/10.3389/fpubh.2022.1017254>
3. Regmi P, Heilbronn LK. Time-Restricted Eating: Benefits, Mechanisms, and Challenges in Translation. *iScience*. 2020 May 15;23(6):101161.
4. Stenvers DJ, Scheer FAJL, Schrauwen P, la Fleur SE, Kalsbeek A. Circadian clocks and insulin resistance. *Nat Rev Endocrinol*. 2019 Feb;15(2):75–89.
5. Longo VD, Mattson MP. Fasting: Molecular Mechanisms and Clinical Applications. *Cell Metabolism*. 2014 Feb 4;19(2):181–92.
6. Anemoulis M, Vlastos A, Kachtsidis V, Karras SN. Intermittent Fasting in Breast Cancer: A Systematic Review and Critical Update of Available Studies. *Nutrients*. 2023 Jan;15(3):532.
7. Di Francesco A, Di Germanio C, Bernier M, de Cabo R. A time to fast. *Science*. 2018 Nov 16;362(6416):770–5.
8. Alshammari K., Alhaidal H., Alharbi R., Alrubaiaan A., Alyousif G., Alkaiyat M., & Abdel-Razaq W.S. (2022). The Impact of Fasting the Holy Month of Ramadan on Colorectal Cancer Patients and Two Tumor Biomarkers: A Tertiary-Care Hospital Experience. *MedRxiv*, (Alshammari, Alyousif, Alkaiyat) King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia(Alhaidal, Abdel-Razaq) College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard He. <https://doi.org/10.1101/2022.08.04.22278413>
9. Badar, T. (2014). Safety and Feasibility of Muslim Fasting While Receiving Chemotherapy. *IOSR Journal of Pharmacy (IOSRPHR)*, 4(1), 15–20. <https://doi.org/10.9790/3013-0401015-20>
10. Champ, C. The effect of intermittent fasting on body composition in women with breast cancer (EFFECT-BC). *ClinicalTrials.gov* identifier: NCT04691999. Updated November 21, 2021. Accessed September 21, 2023. <https://www.clinicaltrials.gov/study/NCT04691999>
11. Chung, C. Effect of prolonged nightly fasting on immunotherapy outcomes of HNSCC – role of gut microbiome. *ClinicalTrials.gov* identifier: NCT05083416. Updated July 3, 2023. Accessed September 26, 2023. <https://www.clinicaltrials.gov/study/NCT05083416>
12. Christensen, R. A., Haykowsky, M. J., Nadler, M., Prado, C. M., Small, S. D., Rickard, J. N., Pituskin, E., Paterson, D. I., Mackey, J. R., Thompson, R. B., & Kirkham, A. A. (2022). Rationale and Design of IMPACT-women: A randomized controlled trial of the effect of time-restricted eating, healthy eating, and reduced sedentary behavior on metabolic health during chemotherapy for early-stage breast cancer. *The British Journal of Nutrition*, az4, 0372547, 1–20. <https://doi.org/10.1017/S0007114522003816>
13. Friedman, D. Overnight fasting after completion of therapy: The OnFACT study. *ClinicalTrials.gov* identifier: NCT03523377. Updated August 21, 2023. Accessed September 21, 2023. <https://www.clinicaltrials.gov/study/NCT03523377>

14. Gabel, K. Time restricted eating during chemotherapy for breast cancer. ClinicalTrials.gov identifier: NCT05259410. Updated April 13, 2023. Accessed September 26, 2023. <https://www.clinicaltrials.gov/study/NCT05259410>
15. Hillengass, J. Non-chemotherapeutic interventions for the improvement of quality of life and immune function in patients with multiple myeloma. ClinicalTrials.gov identifier: NCT05312255. Updated March 1, 2023. Accessed September 26, 2023. <https://www.clinicaltrials.gov/study/NCT05312255>
16. James, R. K. Daily, Long-term intermittent fasting for the prevention of PSA-recurrence in patients with localized prostate cancer after radical prostatectomy. ClinicalTrials.gov identifier: NCT04288336. Updated July 11, 2022. Accessed September 21, 2023. <https://www.clinicaltrials.gov/study/NCT04288336>
17. Kirkham, A. A., Ford, K. L., Topolnyski, J., Da Silva, B. R., Paterson, D. I., Prado, C. M., Joy, A. A., Boule, N. G., Pituskin, E., Haykowsky, M. J., & Thompson, R. B. (2022). Time-Restricted Eating to Reduce Cardiovascular Risk Among Older Breast Cancer Survivors: A Single-Arm Feasibility Study. *JACC. CardioOncology*, 4(2), 276–278. <https://doi.org/10.1016/j.jaccao.2022.03.002>
18. Kirkham A.A., Topolnyski J., Haykowsky M.J., Paterson I., Prado C.M., Joy A.A.A., Boule N., Ford K.L., Andre P.B., Da Silva B.R., Pituskin E., & Thompson R. (2021). Weekday 16:8 time-restricted eating in breast cancer survivors: Feasibility, safety, and effects on cardiometabolic health. *Circulation*, 144(SUPPL 1). <https://doi.org/10.1161/circ.144.suppl-1.12484>
19. Kleckner, A. S., Altman, B. J., Reschke, J. E., Kleckner, I. R., Culakova, E., Dunne, R. F., Mustian, K. M., & Peppone, L. J. (2022). Time-restricted Eating to Address Cancer-related Fatigue among Cancer Survivors: A Single-arm Pilot Study. *Journal of Integrative Oncology*, 11(5).
20. Li, Y. R. Time-restricted eating versus nutritional counseling for the reduction of radiation or chemoradiation tx side effects in patients with prostate, cervical or rectal cancers. ClinicalTrials.gov identifier: NCT05722288. Updated August 24, 2023. Accessed September 26, 2023. <https://www.clinicaltrials.gov/study/NCT05722288>
21. Ligibel, J. Feasibility of fasting and exercise in patients with HR+ MBC. ClinicalTrials.gov identifier: NCT04708860. Updated November 29, 2022. Accessed September 21, 2023. <https://www.clinicaltrials.gov/study/NCT04708860>
22. Marinac, C. R., Nelson, S. H., Breen, C. I., Hartman, S. J., Natarajan, L., Pierce, J. P., Flatt, S. W., Sears, D. D., & Patterson, R. E. (2016). Prolonged Nightly Fasting and Breast Cancer Prognosis. *JAMA Oncology*, 2(8), 1049–1055. <https://doi.org/10.1001/jamaoncol.2016.0164>
23. O'Donnell E., Shapiro Y., Comander A., Isakoff S., Moy B., Spring L., Wander S., Kuter I., Shin J., Specht M., Kournioti C., Hu B., Sullivan C., Winters L., Horick N., & Peppercorn J. (2022). Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast). *Breast Cancer Research and Treatment*, 193(3), 579–587. <https://doi.org/10.1007/s10549-022-06594-4>
24. Palomar-Cros, A., Espinosa, A., Straif, K., Perez-Gomez, B., Papantoniou, K., Gomez-Acebo, I., Molina-Barcelo, A., Olmedo-Requena, R., Alguacil, J., Fernandez-Tardon, G., Casabonne, D., Aragones, N., Castano-Vinyals, G., Pollan, M., Romaguera, D., &

- Kogevinas, M. (2021). The Association of Nighttime Fasting Duration and Prostate Cancer Risk: Results from the Multicase-Control (MCC) Study in Spain. *Nutrients*, 13(8). <https://doi.org/10.3390/nu13082662>
25. Playdon, M. Time restricted eating (TRE) among endometrial cancer patients (TREND). ClinicalTrials.gov identifier: NCT04783467. Updated November 7, 2022. Accessed September 21, 2023. <https://www.clinicaltrials.gov/study/NCT04783467>
  26. Samoa, R. Diabetes prevention program (METFIT) in reducing insulin resistance in stage I-III breast cancer survivors. ClinicalTrials.gov identifier: NCT04560439. Updated June 9, 2022. Accessed September 21, 2023. <https://www.clinicaltrials.gov/study/NCT04560439>
  27. Stringer, E. Intermittent fasting and CLL/SLL. ClinicalTrials.gov identifier: NCT04626843. Updated February 14, 2023. Accessed September 21, 2023. <https://www.clinicaltrials.gov/study/NCT04626843>
  28. Thomas, P. Metformin and nightly fasting in women with early breast cancer. ClinicalTrials.gov identifier: NCT05023967. Updated June 23, 2023. Accessed September 21, 2023. <https://www.clinicaltrials.gov/study/NCT05023967>
  29. Vega C. & Merino T. (2022). Caloric restriction or intermittent fasting in cancer patients receiving curative radiotherapy. *Radiotherapy and Oncology*, 170(Supplement 1), S1028–S1029. <https://doi.org/10.1016/S0167-8140%2822%2903178-4>
  30. Yassin, M. A., Ghasoub, R. S., Aldapt, M. B., Abdulla, M. A., Chandra, P., Shwaylia, H. M., Nashwan, A. J., Kassem, N. A., & Akiki, S. J. (2021). Effects of Intermittent Fasting on Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia: An Outcome of European LeukemiaNet Project. *Cancer Control : Journal of the Moffitt Cancer Center*, 28(dlg, 9438457), 10732748211009256. <https://doi.org/10.1177/10732748211009256>
  31. NA. Intermittent fasting for the improvement of outcomes in patients with stage I-III breast cancer receiving chemotherapy before surgery. ClinicalTrials.gov identifier: NCT05327608. Updated January 26, 2023. Accessed September 26, 2023. <https://www.clinicaltrials.gov/study/NCT05327608>